In around 30% of resistant tumours, resistance to BRAF inhibition is conferred by alternative splicing via generation of BRAF isoforms lacking the RAS binding domain (RBD) encoded by exons 3–5 [7, 11]. Here, BRAF is linked to neoplasm.